Jump to section
IdentificationPharmacologyInteractionsReferencesTrialsEconomicsPropertiesSpectraTaxonomyEtorphine
Identification
- Name
- Etorphine
- Accession Number
- DB01497
- Type
- Small Molecule
- Groups
- Illicit, Vet Approved
- Description
A narcotic analgesic morphinan used as a sedative in veterinary practice. In Hong Kong, Etorphine is regulated under Schedule 1 of Hong Kong's Chapter 134 Dangerous Drugs Ordinance. It can only be used legally by health professionals and for university research purposes. The substance can be given by pharmacists under a prescription. In the US, Etorphine is listed as a Schedule I drug, although Etorphine hydrochloride is classified as Schedule II.
- Structure
Structure for DB01497 (Etorphine)
- Synonyms
- Etorphinum
- External IDs
- DEA No. 9056 / M99
- Product Ingredients
Ingredient UNII CAS InChI Key Etorphine Hydrochloride 8CBE01N748 13764-49-3 JNHPUZURWFYYHW-DTUSRQQPSA-N - Categories
- UNII
- 42M2Y6NU9O
- CAS number
- 14521-96-1
- Weight
- Average: 411.5338
Monoisotopic: 411.240958549 - Chemical Formula
- C25H33NO4
- InChI Key
- CAHCBJPUTCKATP-HBDRVVKHSA-N
- InChI
- InChI=1S/C25H33NO4/c1-5-8-22(2,28)17-14-23-9-10-25(17,29-4)21-24(23)11-12-26(3)18(23)13-15-6-7-16(27)20(30-21)19(15)24/h6-7,9-10,17-18,21,27-28H,5,8,11-14H2,1-4H3/t17?,18-,21?,22?,23-,24+,25?/m1/s1
- IUPAC Name
- (1R,2R,6S)-19-(2-hydroxypentan-2-yl)-15-methoxy-3-methyl-13-oxa-3-azahexacyclo[13.2.2.1²,⁸.0¹,⁶.0⁶,¹⁴.0⁷,¹²]icosa-7,9,11,16-tetraen-11-ol
- SMILES
- [H][[email protected]]12CC3=C4C(OC5[[email protected]@]4(CCN1C)[[email protected]]21CC(C(C)(O)CCC)C5(OC)C=C1)=C(O)C=C3
Pharmacology
- Indication
- Not Available
- Structured Indications
- Not Available
- Pharmacodynamics
Etorphine is a synthetic cousin of morphine and 40,000 times more powerful. It can be produced from thebaine. It is most often used to immobilize elephants and other large mammals. Etorphine is only available legally for veterinary use and is strictly governed by law.
- Mechanism of action
Etorphine is an agonist at mu, delta, and kappa opioid receptors. It also has a weak affinity for the ORL1 nociceptin/orphanin FQ receptor.
Target Actions Organism AMu-type opioid receptor agonistHuman ADelta-type opioid receptor agonistHuman AKappa-type opioid receptor agonistHuman UNociceptin receptor agonistHuman UE3 ubiquitin-protein ligase TRIM13 agonistHuman UPro-opiomelanocortin Not Available Human - Absorption
- Not Available
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
- Not Available
- Route of elimination
- Not Available
- Half life
- Not Available
- Clearance
- Not Available
- Toxicity
- Not Available
- Affected organisms
- Humans and other mammals
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
Drug Interaction Drug group 2,5-Dimethoxy-4-ethylamphetamine 2,5-Dimethoxy-4-ethylamphetamine may increase the analgesic activities of Etorphine. Experimental, Illicit 3,4-Methylenedioxyamphetamine 3,4-Methylenedioxyamphetamine may increase the analgesic activities of Etorphine. Experimental, Illicit 4-Bromo-2,5-dimethoxyamphetamine 4-Bromo-2,5-dimethoxyamphetamine may increase the analgesic activities of Etorphine. Experimental, Illicit 7-Nitroindazole The risk or severity of adverse effects can be increased when Etorphine is combined with 7-Nitroindazole. Experimental 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline The risk or severity of adverse effects can be increased when Etorphine is combined with 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline. Experimental Acepromazine The risk or severity of adverse effects can be increased when Etorphine is combined with Acepromazine. Approved, Vet Approved Aceprometazine The risk or severity of adverse effects can be increased when Etorphine is combined with Aceprometazine. Approved Acetazolamide The risk or severity of adverse effects can be increased when Etorphine is combined with Acetazolamide. Approved, Vet Approved Aclidinium The risk or severity of adverse effects can be increased when Aclidinium is combined with Etorphine. Approved Adipiplon The risk or severity of adverse effects can be increased when Etorphine is combined with Adipiplon. Investigational Agomelatine The risk or severity of adverse effects can be increased when Etorphine is combined with Agomelatine. Approved, Investigational Alaproclate Etorphine may increase the serotonergic activities of Alaproclate. Experimental Alcuronium The risk or severity of adverse effects can be increased when Alcuronium is combined with Etorphine. Experimental Alfaxalone The risk or severity of adverse effects can be increased when Etorphine is combined with Alfaxalone. Vet Approved Alfentanil The risk or severity of adverse effects can be increased when Alfentanil is combined with Etorphine. Approved, Illicit Alimemazine Alimemazine may increase the hypotensive activities of Etorphine. Approved, Vet Approved Allopregnanolone The risk or severity of adverse effects can be increased when Etorphine is combined with Allopregnanolone. Investigational Alphacetylmethadol The risk or severity of adverse effects can be increased when Etorphine is combined with Alphacetylmethadol. Experimental, Illicit Alphaprodine The risk or severity of adverse effects can be increased when Etorphine is combined with Alphaprodine. Illicit Alprazolam The risk or severity of adverse effects can be increased when Alprazolam is combined with Etorphine. Approved, Illicit, Investigational Alvimopan The risk or severity of adverse effects can be increased when Etorphine is combined with Alvimopan. Approved Amiloride The risk or severity of adverse effects can be increased when Etorphine is combined with Amiloride. Approved Amisulpride The risk or severity of adverse effects can be increased when Etorphine is combined with Amisulpride. Approved, Investigational Amitriptyline The risk or severity of adverse effects can be increased when Etorphine is combined with Amitriptyline. Approved Ammonium chloride Ammonium chloride may increase the excretion rate of Etorphine which could result in a lower serum level and potentially a reduction in efficacy. Approved, Vet Approved Amobarbital The risk or severity of adverse effects can be increased when Amobarbital is combined with Etorphine. Approved, Illicit Amoxapine The risk or severity of adverse effects can be increased when Etorphine is combined with Amoxapine. Approved Amperozide The risk or severity of adverse effects can be increased when Etorphine is combined with Amperozide. Experimental Amphetamine Amphetamine may increase the analgesic activities of Etorphine. Approved, Illicit Anisotropine Methylbromide The risk or severity of adverse effects can be increased when Anisotropine Methylbromide is combined with Etorphine. Approved Aripiprazole The risk or severity of adverse effects can be increased when Aripiprazole is combined with Etorphine. Approved, Investigational Articaine The risk or severity of adverse effects can be increased when Etorphine is combined with Articaine. Approved Asenapine The risk or severity of adverse effects can be increased when Asenapine is combined with Etorphine. Approved Atracurium The risk or severity of adverse effects can be increased when Atracurium is combined with Etorphine. Experimental Atracurium besylate The risk or severity of adverse effects can be increased when Atracurium besylate is combined with Etorphine. Approved Atropine The risk or severity of adverse effects can be increased when Atropine is combined with Etorphine. Approved, Vet Approved Azaperone The risk or severity of adverse effects can be increased when Etorphine is combined with Azaperone. Vet Approved Azelastine Etorphine may increase the central nervous system depressant (CNS depressant) activities of Azelastine. Approved Azosemide The risk or severity of adverse effects can be increased when Etorphine is combined with Azosemide. Investigational Baclofen The risk or severity of adverse effects can be increased when Etorphine is combined with Baclofen. Approved Barbital The risk or severity of adverse effects can be increased when Barbital is combined with Etorphine. Illicit Benactyzine The risk or severity of adverse effects can be increased when Benactyzine is combined with Etorphine. Withdrawn Bendroflumethiazide The risk or severity of adverse effects can be increased when Etorphine is combined with Bendroflumethiazide. Approved Benmoxin The risk or severity of adverse effects can be increased when Etorphine is combined with Benmoxin. Withdrawn Benperidol The risk or severity of adverse effects can be increased when Etorphine is combined with Benperidol. Investigational Benzatropine The risk or severity of adverse effects can be increased when Benzatropine is combined with Etorphine. Approved Benzocaine The risk or severity of adverse effects can be increased when Benzocaine is combined with Etorphine. Approved Benzphetamine Benzphetamine may increase the analgesic activities of Etorphine. Approved, Illicit Benzyl alcohol The risk or severity of adverse effects can be increased when Etorphine is combined with Benzyl alcohol. Approved Biperiden The risk or severity of adverse effects can be increased when Biperiden is combined with Etorphine. Approved BL-1020 BL-1020 may increase the hypotensive activities of Etorphine. Investigational Bornaprine The risk or severity of adverse effects can be increased when Bornaprine is combined with Etorphine. Experimental Brexpiprazole The risk or severity of adverse effects can be increased when Etorphine is combined with Brexpiprazole. Approved Brimonidine Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Etorphine. Approved Brofaromine The risk or severity of adverse effects can be increased when Etorphine is combined with Brofaromine. Experimental Bromazepam The risk or severity of adverse effects can be increased when Bromazepam is combined with Etorphine. Approved, Illicit Bromisoval The risk or severity of adverse effects can be increased when Etorphine is combined with Bromisoval. Experimental Bromperidol The risk or severity of adverse effects can be increased when Etorphine is combined with Bromperidol. Investigational Brompheniramine The risk or severity of adverse effects can be increased when Etorphine is combined with Brompheniramine. Approved Brotizolam The risk or severity of adverse effects can be increased when Etorphine is combined with Brotizolam. Approved, Withdrawn Bumetanide The risk or severity of adverse effects can be increased when Etorphine is combined with Bumetanide. Approved Bupivacaine The risk or severity of adverse effects can be increased when Bupivacaine is combined with Etorphine. Approved, Investigational Buprenorphine Etorphine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Approved, Illicit, Investigational, Vet Approved Buspirone The risk or severity of adverse effects can be increased when Buspirone is combined with Etorphine. Approved, Investigational Butabarbital The risk or severity of adverse effects can be increased when Butabarbital is combined with Etorphine. Approved, Illicit Butacaine The risk or severity of adverse effects can be increased when Etorphine is combined with Butacaine. Vet Approved Butalbital The risk or severity of adverse effects can be increased when Etorphine is combined with Butalbital. Approved, Illicit Butamben The risk or severity of adverse effects can be increased when Etorphine is combined with Butamben. Approved Butethal The risk or severity of adverse effects can be increased when Butethal is combined with Etorphine. Approved, Illicit Butorphanol The risk or severity of adverse effects can be increased when Butorphanol is combined with Etorphine. Approved, Illicit, Vet Approved Canertinib The risk or severity of adverse effects can be increased when Etorphine is combined with Canertinib. Investigational Canrenoic acid The risk or severity of adverse effects can be increased when Etorphine is combined with Canrenoic acid. Approved, Withdrawn Canrenone The risk or severity of adverse effects can be increased when Etorphine is combined with Canrenone. Investigational Carbamazepine The risk or severity of adverse effects can be increased when Carbamazepine is combined with Etorphine. Approved, Investigational Carbinoxamine The risk or severity of adverse effects can be increased when Etorphine is combined with Carbinoxamine. Approved Carfentanil The risk or severity of adverse effects can be increased when Etorphine is combined with Carfentanil. Illicit, Vet Approved Carisoprodol The risk or severity of adverse effects can be increased when Etorphine is combined with Carisoprodol. Approved Caroxazone The risk or severity of adverse effects can be increased when Etorphine is combined with Caroxazone. Withdrawn Cetirizine The risk or severity of adverse effects can be increased when Etorphine is combined with Cetirizine. Approved Chloral hydrate The risk or severity of adverse effects can be increased when Etorphine is combined with Chloral hydrate. Approved, Illicit, Vet Approved Chlordiazepoxide The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Etorphine. Approved, Illicit Chlormezanone The risk or severity of adverse effects can be increased when Chlormezanone is combined with Etorphine. Approved, Withdrawn Chloroprocaine The risk or severity of adverse effects can be increased when Chloroprocaine is combined with Etorphine. Approved Chlorothiazide The risk or severity of adverse effects can be increased when Etorphine is combined with Chlorothiazide. Approved, Vet Approved Chlorphenamine The risk or severity of adverse effects can be increased when Etorphine is combined with Chlorphenamine. Approved Chlorphenoxamine The risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Etorphine. Withdrawn Chlorphentermine Chlorphentermine may increase the analgesic activities of Etorphine. Illicit, Withdrawn Chlorproethazine Chlorproethazine may increase the hypotensive activities of Etorphine. Experimental Chlorpromazine The risk or severity of adverse effects can be increased when Chlorpromazine is combined with Etorphine. Approved, Vet Approved Chlorprothixene The risk or severity of adverse effects can be increased when Chlorprothixene is combined with Etorphine. Approved, Withdrawn Chlorthalidone The risk or severity of adverse effects can be increased when Etorphine is combined with Chlorthalidone. Approved Chlorzoxazone The risk or severity of adverse effects can be increased when Etorphine is combined with Chlorzoxazone. Approved Cicletanine The risk or severity of adverse effects can be increased when Etorphine is combined with Cicletanine. Investigational Cinchocaine The risk or severity of adverse effects can be increased when Cinchocaine is combined with Etorphine. Approved, Vet Approved Citalopram Etorphine may increase the serotonergic activities of Citalopram. Approved Clemastine The risk or severity of adverse effects can be increased when Etorphine is combined with Clemastine. Approved Clidinium The risk or severity of adverse effects can be increased when Etorphine is combined with Clidinium. Approved Clobazam The risk or severity of adverse effects can be increased when Etorphine is combined with Clobazam. Approved, Illicit Clofenamide The risk or severity of adverse effects can be increased when Etorphine is combined with Clofenamide. Experimental clomethiazole The risk or severity of adverse effects can be increased when Etorphine is combined with clomethiazole. Investigational Clomipramine The risk or severity of adverse effects can be increased when Etorphine is combined with Clomipramine. Approved, Vet Approved Clonazepam The risk or severity of adverse effects can be increased when Etorphine is combined with Clonazepam. Approved, Illicit Clonidine The risk or severity of adverse effects can be increased when Etorphine is combined with Clonidine. Approved Clopamide The risk or severity of adverse effects can be increased when Etorphine is combined with Clopamide. Experimental Clopenthixol The risk or severity of adverse effects can be increased when Etorphine is combined with Clopenthixol. Experimental Clorazepate The risk or severity of adverse effects can be increased when Clorazepate is combined with Etorphine. Approved, Illicit Clorexolone The risk or severity of adverse effects can be increased when Etorphine is combined with Clorexolone. Experimental Clothiapine The risk or severity of adverse effects can be increased when Etorphine is combined with Clothiapine. Experimental Clozapine The risk or severity of adverse effects can be increased when Clozapine is combined with Etorphine. Approved Cocaine The risk or severity of adverse effects can be increased when Cocaine is combined with Etorphine. Approved, Illicit Codeine The risk or severity of adverse effects can be increased when Codeine is combined with Etorphine. Approved, Illicit Conivaptan The risk or severity of adverse effects can be increased when Etorphine is combined with Conivaptan. Approved, Investigational Cyclizine The risk or severity of adverse effects can be increased when Etorphine is combined with Cyclizine. Approved Cyclobenzaprine The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Etorphine. Approved Cyclopenthiazide The risk or severity of adverse effects can be increased when Etorphine is combined with Cyclopenthiazide. Experimental Cyclopentolate The risk or severity of adverse effects can be increased when Cyclopentolate is combined with Etorphine. Approved Cyclothiazide The risk or severity of adverse effects can be increased when Etorphine is combined with Cyclothiazide. Approved Cyproheptadine The risk or severity of adverse effects can be increased when Etorphine is combined with Cyproheptadine. Approved Dantrolene The risk or severity of adverse effects can be increased when Etorphine is combined with Dantrolene. Approved Dapiprazole The risk or severity of adverse effects can be increased when Dapiprazole is combined with Etorphine. Approved Dapoxetine Etorphine may increase the serotonergic activities of Dapoxetine. Investigational Darifenacin The risk or severity of adverse effects can be increased when Darifenacin is combined with Etorphine. Approved, Investigational Deramciclane The risk or severity of adverse effects can be increased when Etorphine is combined with Deramciclane. Investigational Desflurane The risk or severity of adverse effects can be increased when Desflurane is combined with Etorphine. Approved Desipramine The risk or severity of adverse effects can be increased when Etorphine is combined with Desipramine. Approved Desloratadine The risk or severity of adverse effects can be increased when Etorphine is combined with Desloratadine. Approved, Investigational Desmopressin The risk or severity of adverse effects can be increased when Etorphine is combined with Desmopressin. Approved Desvenlafaxine Etorphine may increase the serotonergic activities of Desvenlafaxine. Approved Detomidine The risk or severity of adverse effects can be increased when Etorphine is combined with Detomidine. Vet Approved Dexbrompheniramine The risk or severity of adverse effects can be increased when Etorphine is combined with Dexbrompheniramine. Approved Dexetimide The risk or severity of adverse effects can be increased when Dexetimide is combined with Etorphine. Withdrawn Dexmedetomidine The risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Etorphine. Approved, Vet Approved Dextroamphetamine Dextroamphetamine may increase the analgesic activities of Etorphine. Approved, Illicit Dextromoramide The risk or severity of adverse effects can be increased when Etorphine is combined with Dextromoramide. Experimental, Illicit Dextropropoxyphene The risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Etorphine. Approved, Illicit, Withdrawn Dezocine The risk or severity of adverse effects can be increased when Dezocine is combined with Etorphine. Approved Diazepam The risk or severity of adverse effects can be increased when Diazepam is combined with Etorphine. Approved, Illicit, Vet Approved Dicyclomine The risk or severity of adverse effects can be increased when Dicyclomine is combined with Etorphine. Approved Diethyl ether The risk or severity of adverse effects can be increased when Etorphine is combined with Diethyl ether. Experimental Diethylpropion Diethylpropion may increase the analgesic activities of Etorphine. Approved, Illicit Difenoxin The risk or severity of adverse effects can be increased when Etorphine is combined with Difenoxin. Approved, Illicit Dihydrocodeine The risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Etorphine. Approved, Illicit Dihydroetorphine The risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Etorphine. Experimental, Illicit Dihydromorphine The risk or severity of adverse effects can be increased when Etorphine is combined with Dihydromorphine. Experimental, Illicit Dimenhydrinate The risk or severity of adverse effects can be increased when Etorphine is combined with Dimenhydrinate. Approved Diphenhydramine The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Etorphine. Approved Diphenoxylate The risk or severity of adverse effects can be increased when Diphenoxylate is combined with Etorphine. Approved, Illicit Dixyrazine The risk or severity of adverse effects can be increased when Etorphine is combined with Dixyrazine. Experimental Doramectin The risk or severity of adverse effects can be increased when Etorphine is combined with Doramectin. Vet Approved Doxepin The risk or severity of adverse effects can be increased when Etorphine is combined with Doxepin. Approved Doxylamine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Etorphine. Approved, Vet Approved DPDPE The risk or severity of adverse effects can be increased when Etorphine is combined with DPDPE. Investigational Dronabinol Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Etorphine. Approved, Illicit Droperidol Droperidol may increase the central nervous system depressant (CNS depressant) activities of Etorphine. Approved, Vet Approved Drospirenone The risk or severity of adverse effects can be increased when Etorphine is combined with Drospirenone. Approved Drotebanol The risk or severity of adverse effects can be increased when Etorphine is combined with Drotebanol. Experimental, Illicit Duloxetine Etorphine may increase the serotonergic activities of Duloxetine. Approved Dyclonine The risk or severity of adverse effects can be increased when Dyclonine is combined with Etorphine. Approved Ecgonine The risk or severity of adverse effects can be increased when Etorphine is combined with Ecgonine. Experimental, Illicit Ecopipam The risk or severity of adverse effects can be increased when Etorphine is combined with Ecopipam. Investigational Efavirenz The risk or severity of adverse effects can be increased when Etorphine is combined with Efavirenz. Approved, Investigational Efonidipine The risk or severity of adverse effects can be increased when Etorphine is combined with Efonidipine. Approved Eltanolone The risk or severity of adverse effects can be increased when Etorphine is combined with Eltanolone. Investigational Eluxadoline Etorphine may increase the constipating activities of Eluxadoline. Approved Emepronium The risk or severity of adverse effects can be increased when Emepronium is combined with Etorphine. Experimental Enflurane The risk or severity of adverse effects can be increased when Enflurane is combined with Etorphine. Approved, Vet Approved Entacapone The risk or severity of adverse effects can be increased when Etorphine is combined with Entacapone. Approved, Investigational Eplerenone The risk or severity of adverse effects can be increased when Etorphine is combined with Eplerenone. Approved Escitalopram Etorphine may increase the serotonergic activities of Escitalopram. Approved, Investigational Estazolam The risk or severity of adverse effects can be increased when Estazolam is combined with Etorphine. Approved, Illicit Eszopiclone The risk or severity of adverse effects can be increased when Eszopiclone is combined with Etorphine. Approved Etacrynic acid The risk or severity of adverse effects can be increased when Etorphine is combined with Etacrynic acid. Approved Etanautine The risk or severity of adverse effects can be increased when Etanautine is combined with Etorphine. Experimental Ethanol Etorphine may increase the central nervous system depressant (CNS depressant) activities of Ethanol. Approved Ethchlorvynol The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Etorphine. Approved, Illicit, Withdrawn Ethopropazine The risk or severity of adverse effects can be increased when Ethopropazine is combined with Etorphine. Approved Ethosuximide The risk or severity of adverse effects can be increased when Etorphine is combined with Ethosuximide. Approved Ethotoin The risk or severity of adverse effects can be increased when Etorphine is combined with Ethotoin. Approved Ethoxzolamide The risk or severity of adverse effects can be increased when Etorphine is combined with Ethoxzolamide. Withdrawn Ethyl carbamate The risk or severity of adverse effects can be increased when Etorphine is combined with Ethyl carbamate. Withdrawn Ethyl chloride The risk or severity of adverse effects can be increased when Etorphine is combined with Ethyl chloride. Experimental Ethyl loflazepate The risk or severity of adverse effects can be increased when Etorphine is combined with Ethyl loflazepate. Approved, Illicit Ethylmorphine The risk or severity of adverse effects can be increased when Ethylmorphine is combined with Etorphine. Approved, Illicit Etidocaine The risk or severity of adverse effects can be increased when Etorphine is combined with Etidocaine. Approved Etifoxine The risk or severity of adverse effects can be increased when Etorphine is combined with Etifoxine. Withdrawn Etizolam The risk or severity of adverse effects can be increased when Etorphine is combined with Etizolam. Approved Etomidate The risk or severity of adverse effects can be increased when Etomidate is combined with Etorphine. Approved Etoperidone Etorphine may increase the serotonergic activities of Etoperidone. Approved Etybenzatropine The risk or severity of adverse effects can be increased when Etybenzatropine is combined with Etorphine. Experimental Ezogabine The risk or severity of adverse effects can be increased when Etorphine is combined with Ezogabine. Approved Felbamate The risk or severity of adverse effects can be increased when Etorphine is combined with Felbamate. Approved Fencamfamine The risk or severity of adverse effects can be increased when Fencamfamine is combined with Etorphine. Approved, Illicit, Withdrawn Fenquizone The risk or severity of adverse effects can be increased when Etorphine is combined with Fenquizone. Experimental Fentanyl The risk or severity of adverse effects can be increased when Fentanyl is combined with Etorphine. Approved, Illicit, Investigational, Vet Approved Fesoterodine The risk or severity of adverse effects can be increased when Fesoterodine is combined with Etorphine. Approved Fexofenadine The risk or severity of adverse effects can be increased when Etorphine is combined with Fexofenadine. Approved Flibanserin The risk or severity of adverse effects can be increased when Etorphine is combined with Flibanserin. Approved Fluanisone The risk or severity of adverse effects can be increased when Etorphine is combined with Fluanisone. Experimental Fludiazepam The risk or severity of adverse effects can be increased when Etorphine is combined with Fludiazepam. Approved, Illicit Flunarizine The risk or severity of adverse effects can be increased when Etorphine is combined with Flunarizine. Approved Flunitrazepam The risk or severity of adverse effects can be increased when Etorphine is combined with Flunitrazepam. Approved, Illicit Fluoxetine Etorphine may increase the serotonergic activities of Fluoxetine. Approved, Vet Approved Flupentixol The risk or severity of adverse effects can be increased when Flupentixol is combined with Etorphine. Approved, Withdrawn Fluphenazine The risk or severity of adverse effects can be increased when Fluphenazine is combined with Etorphine. Approved Flurazepam The risk or severity of adverse effects can be increased when Flurazepam is combined with Etorphine. Approved, Illicit Fluspirilene The risk or severity of adverse effects can be increased when Etorphine is combined with Fluspirilene. Approved Fluticasone propionate The risk or severity of adverse effects can be increased when Etorphine is combined with Fluticasone propionate. Approved Fluvoxamine The risk or severity of adverse effects can be increased when Fluvoxamine is combined with Etorphine. Approved, Investigational Fosphenytoin The risk or severity of adverse effects can be increased when Etorphine is combined with Fosphenytoin. Approved Fospropofol The risk or severity of adverse effects can be increased when Etorphine is combined with Fospropofol. Approved, Illicit Furazolidone The risk or severity of adverse effects can be increased when Etorphine is combined with Furazolidone. Approved, Vet Approved Furosemide The risk or severity of adverse effects can be increased when Etorphine is combined with Furosemide. Approved, Vet Approved Gabapentin The risk or severity of adverse effects can be increased when Gabapentin is combined with Etorphine. Approved, Investigational Gabapentin Enacarbil The risk or severity of adverse effects can be increased when Etorphine is combined with Gabapentin Enacarbil. Approved Gallamine The risk or severity of adverse effects can be increased when Gallamine is combined with Etorphine. Experimental Gallamine Triethiodide The risk or severity of adverse effects can be increased when Gallamine Triethiodide is combined with Etorphine. Approved Gamma Hydroxybutyric Acid The risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Etorphine. Approved, Illicit Gepefrine Gepefrine may increase the analgesic activities of Etorphine. Experimental Gepirone The risk or severity of adverse effects can be increased when Etorphine is combined with Gepirone. Investigational Glutethimide The risk or severity of adverse effects can be increased when Glutethimide is combined with Etorphine. Approved, Illicit Glycopyrronium The risk or severity of adverse effects can be increased when Glycopyrronium is combined with Etorphine. Approved, Investigational, Vet Approved Guanfacine The risk or severity of adverse effects can be increased when Etorphine is combined with Guanfacine. Approved, Investigational Halazepam The risk or severity of adverse effects can be increased when Halazepam is combined with Etorphine. Approved, Illicit, Withdrawn Haloperidol The risk or severity of adverse effects can be increased when Haloperidol is combined with Etorphine. Approved Halothane The risk or severity of adverse effects can be increased when Halothane is combined with Etorphine. Approved, Vet Approved Harmaline The risk or severity of adverse effects can be increased when Etorphine is combined with Harmaline. Experimental Heroin The risk or severity of adverse effects can be increased when Heroin is combined with Etorphine. Approved, Illicit Hexamethonium The risk or severity of adverse effects can be increased when Hexamethonium is combined with Etorphine. Experimental Hexobarbital The risk or severity of adverse effects can be increased when Hexobarbital is combined with Etorphine. Approved Homatropine The risk or severity of adverse effects can be increased when Homatropine is combined with Etorphine. Approved Hydracarbazine The risk or severity of adverse effects can be increased when Etorphine is combined with Hydracarbazine. Experimental Hydrochlorothiazide The risk or severity of adverse effects can be increased when Etorphine is combined with Hydrochlorothiazide. Approved, Vet Approved Hydrocodone Etorphine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone. Approved, Illicit Hydroflumethiazide The risk or severity of adverse effects can be increased when Etorphine is combined with Hydroflumethiazide. Approved Hydromorphone The risk or severity of adverse effects can be increased when Hydromorphone is combined with Etorphine. Approved, Illicit Hydroxyamphetamine Hydroxyamphetamine may increase the analgesic activities of Etorphine. Approved Hydroxyzine Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Etorphine. Approved Hyoscyamine The risk or severity of adverse effects can be increased when Hyoscyamine is combined with Etorphine. Approved Ibopamine The risk or severity of adverse effects can be increased when Etorphine is combined with Ibopamine. Experimental Iloperidone The risk or severity of adverse effects can be increased when Etorphine is combined with Iloperidone. Approved Imipramine The risk or severity of adverse effects can be increased when Etorphine is combined with Imipramine. Approved Indalpine Etorphine may increase the serotonergic activities of Indalpine. Investigational, Withdrawn Indapamide The risk or severity of adverse effects can be increased when Etorphine is combined with Indapamide. Approved Indiplon The risk or severity of adverse effects can be increased when Etorphine is combined with Indiplon. Investigational Iofetamine I-123 Iofetamine I-123 may increase the analgesic activities of Etorphine. Approved Ipratropium bromide The risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Etorphine. Approved Iproclozide The risk or severity of adverse effects can be increased when Etorphine is combined with Iproclozide. Withdrawn Iproniazid The risk or severity of adverse effects can be increased when Etorphine is combined with Iproniazid. Withdrawn Isocarboxazid The risk or severity of adverse effects can be increased when Etorphine is combined with Isocarboxazid. Approved Isoflurane The risk or severity of adverse effects can be increased when Isoflurane is combined with Etorphine. Approved, Vet Approved Isosorbide The risk or severity of adverse effects can be increased when Etorphine is combined with Isosorbide. Approved Ketamine The risk or severity of adverse effects can be increased when Ketamine is combined with Etorphine. Approved, Vet Approved Ketazolam The risk or severity of adverse effects can be increased when Etorphine is combined with Ketazolam. Approved Ketobemidone The risk or severity of adverse effects can be increased when Etorphine is combined with Ketobemidone. Approved Lamotrigine The risk or severity of adverse effects can be increased when Etorphine is combined with Lamotrigine. Approved, Investigational Levetiracetam The risk or severity of adverse effects can be increased when Etorphine is combined with Levetiracetam. Approved, Investigational Levobupivacaine The risk or severity of adverse effects can be increased when Levobupivacaine is combined with Etorphine. Approved Levocabastine The risk or severity of adverse effects can be increased when Etorphine is combined with Levocabastine. Approved Levocetirizine The risk or severity of adverse effects can be increased when Etorphine is combined with Levocetirizine. Approved Levodopa The risk or severity of adverse effects can be increased when Etorphine is combined with Levodopa. Approved Levomethadyl Acetate The risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Etorphine. Approved Levomilnacipran Etorphine may increase the serotonergic activities of Levomilnacipran. Approved Levorphanol The risk or severity of adverse effects can be increased when Levorphanol is combined with Etorphine. Approved Lidocaine The risk or severity of adverse effects can be increased when Lidocaine is combined with Etorphine. Approved, Vet Approved Lisdexamfetamine Lisdexamfetamine may increase the analgesic activities of Etorphine. Approved, Investigational Lithium The risk or severity of adverse effects can be increased when Lithium is combined with Etorphine. Approved Lofentanil The risk or severity of adverse effects can be increased when Etorphine is combined with Lofentanil. Illicit Loprazolam The risk or severity of adverse effects can be increased when Etorphine is combined with Loprazolam. Experimental Loratadine The risk or severity of adverse effects can be increased when Etorphine is combined with Loratadine. Approved Lorazepam The risk or severity of adverse effects can be increased when Lorazepam is combined with Etorphine. Approved Lormetazepam The risk or severity of adverse effects can be increased when Etorphine is combined with Lormetazepam. Approved Loxapine The risk or severity of adverse effects can be increased when Loxapine is combined with Etorphine. Approved Lurasidone The risk or severity of adverse effects can be increased when Lurasidone is combined with Etorphine. Approved Magnesium Sulfate Magnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Etorphine. Approved, Vet Approved Mannitol The risk or severity of adverse effects can be increased when Etorphine is combined with Mannitol. Approved, Investigational Maprotiline The risk or severity of adverse effects can be increased when Etorphine is combined with Maprotiline. Approved Mazaticol The risk or severity of adverse effects can be increased when Mazaticol is combined with Etorphine. Experimental Mebanazine The risk or severity of adverse effects can be increased when Etorphine is combined with Mebanazine. Withdrawn Mebicar The risk or severity of adverse effects can be increased when Etorphine is combined with Mebicar. Experimental Mebutizide The risk or severity of adverse effects can be increased when Etorphine is combined with Mebutizide. Experimental Mecamylamine The risk or severity of adverse effects can be increased when Mecamylamine is combined with Etorphine. Approved Meclizine The risk or severity of adverse effects can be increased when Etorphine is combined with Meclizine. Approved Medazepam The risk or severity of adverse effects can be increased when Etorphine is combined with Medazepam. Experimental Medetomidine The risk or severity of adverse effects can be increased when Etorphine is combined with Medetomidine. Vet Approved Mefruside The risk or severity of adverse effects can be increased when Etorphine is combined with Mefruside. Experimental Melatonin The risk or severity of adverse effects can be increased when Melatonin is combined with Etorphine. Approved, Nutraceutical, Vet Approved Melperone The risk or severity of adverse effects can be increased when Etorphine is combined with Melperone. Approved Mephedrone Mephedrone may increase the analgesic activities of Etorphine. Investigational Mephentermine Mephentermine may increase the analgesic activities of Etorphine. Approved Mepivacaine The risk or severity of adverse effects can be increased when Mepivacaine is combined with Etorphine. Approved, Vet Approved Meprobamate The risk or severity of adverse effects can be increased when Meprobamate is combined with Etorphine. Approved, Illicit Meptazinol The risk or severity of adverse effects can be increased when Etorphine is combined with Meptazinol. Experimental Mersalyl The risk or severity of adverse effects can be increased when Etorphine is combined with Mersalyl. Approved Mesoridazine The risk or severity of adverse effects can be increased when Mesoridazine is combined with Etorphine. Approved Metaxalone The risk or severity of adverse effects can be increased when Etorphine is combined with Metaxalone. Approved Methadone The risk or severity of adverse effects can be increased when Methadone is combined with Etorphine. Approved Methadyl Acetate The risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Etorphine. Approved, Illicit Methamphetamine Methamphetamine may increase the analgesic activities of Etorphine. Approved, Illicit Methantheline The risk or severity of adverse effects can be increased when Methantheline is combined with Etorphine. Approved Methapyrilene The risk or severity of adverse effects can be increased when Etorphine is combined with Methapyrilene. Withdrawn Methaqualone The risk or severity of adverse effects can be increased when Etorphine is combined with Methaqualone. Illicit, Withdrawn Methazolamide The risk or severity of adverse effects can be increased when Etorphine is combined with Methazolamide. Approved Methocarbamol The risk or severity of adverse effects can be increased when Etorphine is combined with Methocarbamol. Approved, Vet Approved Methohexital The risk or severity of adverse effects can be increased when Methohexital is combined with Etorphine. Approved Methotrimeprazine Etorphine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine. Approved Methoxyflurane The risk or severity of adverse effects can be increased when Methoxyflurane is combined with Etorphine. Approved, Vet Approved Methoxyphenamine Methoxyphenamine may increase the analgesic activities of Etorphine. Experimental Methsuximide The risk or severity of adverse effects can be increased when Etorphine is combined with Methsuximide. Approved Methyclothiazide The risk or severity of adverse effects can be increased when Etorphine is combined with Methyclothiazide. Approved Methylecgonine The risk or severity of adverse effects can be increased when Etorphine is combined with Methylecgonine. Experimental Methylene blue Methylene blue may increase the hypotensive activities of Etorphine. Investigational Methylphenobarbital The risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Etorphine. Approved Meticrane The risk or severity of adverse effects can be increased when Etorphine is combined with Meticrane. Experimental Metixene The risk or severity of adverse effects can be increased when Metixene is combined with Etorphine. Approved Metolazone The risk or severity of adverse effects can be increased when Etorphine is combined with Metolazone. Approved Metyrosine Etorphine may increase the sedative activities of Metyrosine. Approved Midazolam The risk or severity of adverse effects can be increased when Midazolam is combined with Etorphine. Approved, Illicit Midomafetamine 3,4-Methylenedioxymethamphetamine may increase the analgesic activities of Etorphine. Experimental, Illicit Milnacipran Etorphine may increase the serotonergic activities of Milnacipran. Approved Minaprine The risk or severity of adverse effects can be increased when Etorphine is combined with Minaprine. Approved Minocycline Minocycline may increase the central nervous system depressant (CNS depressant) activities of Etorphine. Approved, Investigational Mirtazapine Etorphine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine. Approved MMDA MMDA may increase the analgesic activities of Etorphine. Experimental, Illicit Moclobemide The risk or severity of adverse effects can be increased when Etorphine is combined with Moclobemide. Approved Molindone The risk or severity of adverse effects can be increased when Etorphine is combined with Molindone. Approved Moricizine Moricizine may increase the hypotensive activities of Etorphine. Approved, Withdrawn Morphine The risk or severity of adverse effects can be increased when Morphine is combined with Etorphine. Approved, Investigational Muzolimine The risk or severity of adverse effects can be increased when Etorphine is combined with Muzolimine. Experimental Nabilone Nabilone may increase the central nervous system depressant (CNS depressant) activities of Etorphine. Approved, Investigational Nalbuphine The risk or severity of adverse effects can be increased when Nalbuphine is combined with Etorphine. Approved Naltrexone The therapeutic efficacy of Etorphine can be decreased when used in combination with Naltrexone. Approved, Investigational, Vet Approved Nefazodone Etorphine may increase the serotonergic activities of Nefazodone. Approved, Withdrawn Nialamide The risk or severity of adverse effects can be increased when Etorphine is combined with Nialamide. Withdrawn Nitrazepam The risk or severity of adverse effects can be increased when Nitrazepam is combined with Etorphine. Approved Nitrous oxide The risk or severity of adverse effects can be increased when Nitrous oxide is combined with Etorphine. Approved, Vet Approved Norflurane The risk or severity of adverse effects can be increased when Etorphine is combined with Norflurane. Investigational Normethadone The risk or severity of adverse effects can be increased when Etorphine is combined with Normethadone. Approved, Illicit Nortriptyline The risk or severity of adverse effects can be increased when Etorphine is combined with Nortriptyline. Approved Octamoxin The risk or severity of adverse effects can be increased when Etorphine is combined with Octamoxin. Withdrawn Olanzapine The risk or severity of adverse effects can be increased when Olanzapine is combined with Etorphine. Approved, Investigational Olopatadine The risk or severity of adverse effects can be increased when Etorphine is combined with Olopatadine. Approved Ondansetron The risk or severity of adverse effects can be increased when Ondansetron is combined with Etorphine. Approved Opium The risk or severity of adverse effects can be increased when Etorphine is combined with Opium. Approved, Illicit Orphenadrine Etorphine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine. Approved Osanetant The risk or severity of adverse effects can be increased when Etorphine is combined with Osanetant. Investigational Otilonium The risk or severity of adverse effects can be increased when Otilonium is combined with Etorphine. Experimental Oxazepam The risk or severity of adverse effects can be increased when Oxazepam is combined with Etorphine. Approved Oxethazaine The risk or severity of adverse effects can be increased when Etorphine is combined with Oxethazaine. Investigational Oxitropium The risk or severity of adverse effects can be increased when Oxitropium is combined with Etorphine. Investigational Oxprenolol The risk or severity of adverse effects can be increased when Etorphine is combined with Oxprenolol. Approved Oxybuprocaine The risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Etorphine. Approved Oxybutynin The risk or severity of adverse effects can be increased when Oxybutynin is combined with Etorphine. Approved, Investigational Oxycodone The risk or severity of adverse effects can be increased when Oxycodone is combined with Etorphine. Approved, Illicit, Investigational Oxymorphone The risk or severity of adverse effects can be increased when Oxymorphone is combined with Etorphine. Approved, Investigational, Vet Approved Oxyphenonium The risk or severity of adverse effects can be increased when Oxyphenonium is combined with Etorphine. Approved Paliperidone The risk or severity of adverse effects can be increased when Paliperidone is combined with Etorphine. Approved Pancuronium The risk or severity of adverse effects can be increased when Pancuronium is combined with Etorphine. Approved Paraldehyde Etorphine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde. Approved Pargyline The risk or severity of adverse effects can be increased when Etorphine is combined with Pargyline. Approved Paroxetine Etorphine may increase the serotonergic activities of Paroxetine. Approved, Investigational Pegvisomant The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Etorphine. Approved Penfluridol The risk or severity of adverse effects can be increased when Etorphine is combined with Penfluridol. Experimental Pentazocine The risk or severity of adverse effects can be increased when Pentazocine is combined with Etorphine. Approved, Vet Approved Pentobarbital The risk or severity of adverse effects can be increased when Pentobarbital is combined with Etorphine. Approved, Vet Approved Pentolinium The risk or severity of adverse effects can be increased when Pentolinium is combined with Etorphine. Approved Perampanel Perampanel may increase the central nervous system depressant (CNS depressant) activities of Etorphine. Approved Perazine The risk or severity of adverse effects can be increased when Etorphine is combined with Perazine. Investigational Perospirone The risk or severity of adverse effects can be increased when Etorphine is combined with Perospirone. Approved Perphenazine The risk or severity of adverse effects can be increased when Perphenazine is combined with Etorphine. Approved Pethidine The risk or severity of adverse effects can be increased when Pethidine is combined with Etorphine. Approved Phenazocine The risk or severity of adverse effects can be increased when Etorphine is combined with Phenazocine. Experimental Phenelzine The risk or severity of adverse effects can be increased when Etorphine is combined with Phenelzine. Approved Phenglutarimide The risk or severity of adverse effects can be increased when Phenglutarimide is combined with Etorphine. Experimental Phenibut The risk or severity of adverse effects can be increased when Etorphine is combined with Phenibut. Experimental Pheniprazine The risk or severity of adverse effects can be increased when Etorphine is combined with Pheniprazine. Withdrawn Phenobarbital The risk or severity of adverse effects can be increased when Phenobarbital is combined with Etorphine. Approved Phenoperidine The risk or severity of adverse effects can be increased when Etorphine is combined with Phenoperidine. Experimental Phenoxyethanol The risk or severity of adverse effects can be increased when Etorphine is combined with Phenoxyethanol. Approved Phenoxypropazine The risk or severity of adverse effects can be increased when Etorphine is combined with Phenoxypropazine. Withdrawn Phentermine Phentermine may increase the analgesic activities of Etorphine. Approved, Illicit Phenytoin The risk or severity of adverse effects can be increased when Etorphine is combined with Phenytoin. Approved, Vet Approved Pimozide The risk or severity of adverse effects can be increased when Pimozide is combined with Etorphine. Approved Pipamperone The risk or severity of adverse effects can be increased when Etorphine is combined with Pipamperone. Approved Pipecuronium The risk or severity of adverse effects can be increased when Pipecuronium is combined with Etorphine. Approved Pipotiazine The risk or severity of adverse effects can be increased when Etorphine is combined with Pipotiazine. Approved Pirenzepine The risk or severity of adverse effects can be increased when Pirenzepine is combined with Etorphine. Approved Piretanide The risk or severity of adverse effects can be increased when Etorphine is combined with Piretanide. Experimental Piritramide The risk or severity of adverse effects can be increased when Etorphine is combined with Piritramide. Investigational Pirlindole The risk or severity of adverse effects can be increased when Etorphine is combined with Pirlindole. Approved Pivhydrazine The risk or severity of adverse effects can be increased when Etorphine is combined with Pivhydrazine. Withdrawn Pizotifen The risk or severity of adverse effects can be increased when Etorphine is combined with Pizotifen. Approved Polythiazide The risk or severity of adverse effects can be increased when Etorphine is combined with Polythiazide. Approved Pomalidomide The risk or severity of adverse effects can be increased when Etorphine is combined with Pomalidomide. Approved Potassium The risk or severity of adverse effects can be increased when Etorphine is combined with Potassium. Approved Potassium Citrate The risk or severity of adverse effects can be increased when Etorphine is combined with Potassium Citrate. Approved, Vet Approved Pramipexole Etorphine may increase the sedative activities of Pramipexole. Approved, Investigational Pramocaine The risk or severity of adverse effects can be increased when Etorphine is combined with Pramocaine. Approved Prazepam The risk or severity of adverse effects can be increased when Etorphine is combined with Prazepam. Approved, Illicit Pregabalin The risk or severity of adverse effects can be increased when Pregabalin is combined with Etorphine. Approved, Illicit, Investigational Prilocaine The risk or severity of adverse effects can be increased when Prilocaine is combined with Etorphine. Approved Primidone The risk or severity of adverse effects can be increased when Etorphine is combined with Primidone. Approved, Vet Approved Procaine The risk or severity of adverse effects can be increased when Procaine is combined with Etorphine. Approved, Investigational, Vet Approved Prochlorperazine The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Etorphine. Approved, Vet Approved Procyclidine The risk or severity of adverse effects can be increased when Procyclidine is combined with Etorphine. Approved Promazine The risk or severity of adverse effects can be increased when Promazine is combined with Etorphine. Approved, Vet Approved Promethazine The risk or severity of adverse effects can be increased when Etorphine is combined with Promethazine. Approved Propanidid The risk or severity of adverse effects can be increased when Etorphine is combined with Propanidid. Experimental Propantheline The risk or severity of adverse effects can be increased when Propantheline is combined with Etorphine. Approved Proparacaine The risk or severity of adverse effects can be increased when Proparacaine is combined with Etorphine. Approved, Vet Approved Propiopromazine Propiopromazine may increase the hypotensive activities of Etorphine. Vet Approved Propiverine The risk or severity of adverse effects can be increased when Propiverine is combined with Etorphine. Investigational Propofol The risk or severity of adverse effects can be increased when Propofol is combined with Etorphine. Approved, Investigational, Vet Approved Propoxycaine The risk or severity of adverse effects can be increased when Etorphine is combined with Propoxycaine. Approved Protriptyline The risk or severity of adverse effects can be increased when Etorphine is combined with Protriptyline. Approved Proxibarbal The risk or severity of adverse effects can be increased when Etorphine is combined with Proxibarbal. Experimental PSD502 The risk or severity of adverse effects can be increased when Etorphine is combined with PSD502. Investigational Pseudoephedrine Pseudoephedrine may increase the analgesic activities of Etorphine. Approved Quazepam The risk or severity of adverse effects can be increased when Quazepam is combined with Etorphine. Approved, Illicit Quetiapine The risk or severity of adverse effects can be increased when Quetiapine is combined with Etorphine. Approved Quinethazone The risk or severity of adverse effects can be increased when Etorphine is combined with Quinethazone. Approved Quinidine The risk or severity of adverse effects can be increased when Quinidine is combined with Etorphine. Approved Quinisocaine The risk or severity of adverse effects can be increased when Etorphine is combined with Quinisocaine. Experimental Raclopride The risk or severity of adverse effects can be increased when Etorphine is combined with Raclopride. Investigational Ramelteon The risk or severity of adverse effects can be increased when Etorphine is combined with Ramelteon. Approved, Investigational Ramosetron Etorphine may increase the constipating activities of Ramosetron. Approved Rasagiline The risk or severity of adverse effects can be increased when Etorphine is combined with Rasagiline. Approved Remifentanil The risk or severity of adverse effects can be increased when Remifentanil is combined with Etorphine. Approved Remoxipride The risk or severity of adverse effects can be increased when Remoxipride is combined with Etorphine. Approved, Withdrawn Reserpine The risk or severity of adverse effects can be increased when Reserpine is combined with Etorphine. Approved Risperidone The risk or severity of adverse effects can be increased when Risperidone is combined with Etorphine. Approved, Investigational Ritanserin The risk or severity of adverse effects can be increased when Etorphine is combined with Ritanserin. Investigational Ritobegron Ritobegron may increase the analgesic activities of Etorphine. Investigational Rolofylline The risk or severity of adverse effects can be increased when Etorphine is combined with Rolofylline. Investigational Romifidine The risk or severity of adverse effects can be increased when Etorphine is combined with Romifidine. Vet Approved Ropinirole Etorphine may increase the sedative activities of Ropinirole. Approved, Investigational Ropivacaine The risk or severity of adverse effects can be increased when Ropivacaine is combined with Etorphine. Approved Rotigotine Etorphine may increase the sedative activities of Rotigotine. Approved Rufinamide The risk or severity of adverse effects can be increased when Rufinamide is combined with Etorphine. Approved Safrazine The risk or severity of adverse effects can be increased when Etorphine is combined with Safrazine. Withdrawn Scopolamine The risk or severity of adverse effects can be increased when Etorphine is combined with Scopolamine. Approved Scopolamine butylbromide The risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Etorphine. Approved, Vet Approved Secobarbital The risk or severity of adverse effects can be increased when Secobarbital is combined with Etorphine. Approved, Vet Approved Selegiline The risk or severity of adverse effects can be increased when Etorphine is combined with Selegiline. Approved, Investigational, Vet Approved Sepranolone The risk or severity of adverse effects can be increased when Etorphine is combined with Sepranolone. Investigational Sertindole The risk or severity of adverse effects can be increased when Etorphine is combined with Sertindole. Approved, Withdrawn Sertraline Etorphine may increase the serotonergic activities of Sertraline. Approved Sevoflurane The risk or severity of adverse effects can be increased when Sevoflurane is combined with Etorphine. Approved, Vet Approved Sodium oxybate Sodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Etorphine. Approved Solifenacin The risk or severity of adverse effects can be increased when Solifenacin is combined with Etorphine. Approved Spiradoline The risk or severity of adverse effects can be increased when Etorphine is combined with Spiradoline. Investigational Spironolactone The risk or severity of adverse effects can be increased when Etorphine is combined with Spironolactone. Approved Stiripentol The risk or severity of adverse effects can be increased when Etorphine is combined with Stiripentol. Approved Succinylcholine Succinylcholine may increase the bradycardic activities of Etorphine. Approved Sufentanil The risk or severity of adverse effects can be increased when Sufentanil is combined with Etorphine. Approved, Investigational Sulpiride The risk or severity of adverse effects can be increased when Sulpiride is combined with Etorphine. Approved Sultopride The risk or severity of adverse effects can be increased when Etorphine is combined with Sultopride. Experimental Suvorexant Etorphine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant. Approved Tandospirone The risk or severity of adverse effects can be increased when Etorphine is combined with Tandospirone. Investigational Tapentadol Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Etorphine. Approved Tasimelteon The risk or severity of adverse effects can be increased when Etorphine is combined with Tasimelteon. Approved Temazepam The risk or severity of adverse effects can be increased when Temazepam is combined with Etorphine. Approved Tetrabenazine The risk or severity of adverse effects can be increased when Etorphine is combined with Tetrabenazine. Approved Tetracaine The risk or severity of adverse effects can be increased when Etorphine is combined with Tetracaine. Approved, Vet Approved Tetrahydropalmatine The risk or severity of adverse effects can be increased when Etorphine is combined with Tetrahydropalmatine. Investigational Tetrodotoxin The risk or severity of adverse effects can be increased when Etorphine is combined with Tetrodotoxin. Investigational Thalidomide Etorphine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide. Approved, Investigational, Withdrawn Theobromine The risk or severity of adverse effects can be increased when Etorphine is combined with Theobromine. Approved Thiamylal The risk or severity of adverse effects can be increased when Thiamylal is combined with Etorphine. Approved, Vet Approved Thiazinam Thiazinam may increase the hypotensive activities of Etorphine. Experimental Thiethylperazine Thiethylperazine may increase the hypotensive activities of Etorphine. Withdrawn Thiopental The risk or severity of adverse effects can be increased when Thiopental is combined with Etorphine. Approved, Vet Approved Thioridazine The risk or severity of adverse effects can be increased when Thioridazine is combined with Etorphine. Withdrawn Thiothixene The risk or severity of adverse effects can be increased when Thiothixene is combined with Etorphine. Approved Tiagabine The risk or severity of adverse effects can be increased when Etorphine is combined with Tiagabine. Approved Tiapride The risk or severity of adverse effects can be increased when Etorphine is combined with Tiapride. Approved, Investigational Ticrynafen The risk or severity of adverse effects can be increased when Etorphine is combined with Ticrynafen. Withdrawn Tiletamine The risk or severity of adverse effects can be increased when Etorphine is combined with Tiletamine. Vet Approved Tilidine The risk or severity of adverse effects can be increased when Etorphine is combined with Tilidine. Experimental Tiotropium The risk or severity of adverse effects can be increased when Tiotropium is combined with Etorphine. Approved Tizanidine The risk or severity of adverse effects can be increased when Etorphine is combined with Tizanidine. Approved Tolcapone The risk or severity of adverse effects can be increased when Etorphine is combined with Tolcapone. Approved, Withdrawn Toloxatone The risk or severity of adverse effects can be increased when Etorphine is combined with Toloxatone. Approved Tolterodine The risk or severity of adverse effects can be increased when Tolterodine is combined with Etorphine. Approved, Investigational Tolvaptan The risk or severity of adverse effects can be increased when Etorphine is combined with Tolvaptan. Approved Topiramate The risk or severity of adverse effects can be increased when Etorphine is combined with Topiramate. Approved Torasemide The risk or severity of adverse effects can be increased when Etorphine is combined with Torasemide. Approved Tramadol The risk or severity of adverse effects can be increased when Tramadol is combined with Etorphine. Approved, Investigational Trans-2-Phenylcyclopropylamine The risk or severity of adverse effects can be increased when Etorphine is combined with Trans-2-Phenylcyclopropylamine. Experimental Tranylcypromine The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Etorphine. Approved Trazodone The risk or severity of adverse effects can be increased when Trazodone is combined with Etorphine. Approved, Investigational Triamterene The risk or severity of adverse effects can be increased when Etorphine is combined with Triamterene. Approved Triazolam The risk or severity of adverse effects can be increased when Triazolam is combined with Etorphine. Approved Tricaine methanesulfonate The risk or severity of adverse effects can be increased when Etorphine is combined with Tricaine methanesulfonate. Vet Approved Trichlormethiazide The risk or severity of adverse effects can be increased when Etorphine is combined with Trichlormethiazide. Approved, Vet Approved Trichloroethylene The risk or severity of adverse effects can be increased when Etorphine is combined with Trichloroethylene. Experimental Trifluoperazine The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Etorphine. Approved Trifluperidol The risk or severity of adverse effects can be increased when Etorphine is combined with Trifluperidol. Experimental Triflupromazine The risk or severity of adverse effects can be increased when Triflupromazine is combined with Etorphine. Approved, Vet Approved Trihexyphenidyl The risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Etorphine. Approved Trimethaphan The risk or severity of adverse effects can be increased when Trimethaphan is combined with Etorphine. Approved Trimipramine The risk or severity of adverse effects can be increased when Etorphine is combined with Trimipramine. Approved Triprolidine The risk or severity of adverse effects can be increased when Etorphine is combined with Triprolidine. Approved Tropatepine The risk or severity of adverse effects can be increased when Tropatepine is combined with Etorphine. Experimental Tropicamide The risk or severity of adverse effects can be increased when Tropicamide is combined with Etorphine. Approved Trospium The risk or severity of adverse effects can be increased when Trospium is combined with Etorphine. Approved Tubocurarine The risk or severity of adverse effects can be increased when Tubocurarine is combined with Etorphine. Approved Ularitide The risk or severity of adverse effects can be increased when Etorphine is combined with Ularitide. Investigational Valproic Acid The risk or severity of adverse effects can be increased when Valproic Acid is combined with Etorphine. Approved, Investigational Vecuronium The risk or severity of adverse effects can be increased when Vecuronium is combined with Etorphine. Approved Venlafaxine Etorphine may increase the serotonergic activities of Venlafaxine. Approved Veralipride The risk or severity of adverse effects can be increased when Etorphine is combined with Veralipride. Experimental Vigabatrin The risk or severity of adverse effects can be increased when Etorphine is combined with Vigabatrin. Approved Vinyl ether The risk or severity of adverse effects can be increased when Etorphine is combined with Vinyl ether. Experimental Vortioxetine The risk or severity of adverse effects can be increased when Etorphine is combined with Vortioxetine. Approved Xenon The risk or severity of adverse effects can be increased when Etorphine is combined with Xenon. Experimental Xipamide The risk or severity of adverse effects can be increased when Etorphine is combined with Xipamide. Experimental Xylazine The risk or severity of adverse effects can be increased when Etorphine is combined with Xylazine. Vet Approved Zaleplon The risk or severity of adverse effects can be increased when Zaleplon is combined with Etorphine. Approved, Illicit, Investigational Ziconotide The risk or severity of adverse effects can be increased when Etorphine is combined with Ziconotide. Approved Zimelidine Etorphine may increase the serotonergic activities of Zimelidine. Withdrawn Ziprasidone The risk or severity of adverse effects can be increased when Ziprasidone is combined with Etorphine. Approved Zolazepam The risk or severity of adverse effects can be increased when Etorphine is combined with Zolazepam. Vet Approved Zolpidem Etorphine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. Approved Zonisamide The risk or severity of adverse effects can be increased when Etorphine is combined with Zonisamide. Approved, Investigational Zopiclone The risk or severity of adverse effects can be increased when Zopiclone is combined with Etorphine. Approved Zotepine The risk or severity of adverse effects can be increased when Etorphine is combined with Zotepine. Approved Zuclopenthixol The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Etorphine. Approved, Investigational - Food Interactions
- Not Available
References
- General References
- Not Available
- External Links
Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 214-217 °C PhysProp logP 2.79 SANGSTER (1993) - Predicted Properties
Property Value Source Water Solubility 0.112 mg/mL ALOGPS logP 3.29 ALOGPS logP 2.47 ChemAxon logS -3.6 ALOGPS pKa (Strongest Acidic) 7.48 ChemAxon pKa (Strongest Basic) 11.72 ChemAxon Physiological Charge 1 ChemAxon Hydrogen Acceptor Count 5 ChemAxon Hydrogen Donor Count 2 ChemAxon Polar Surface Area 62.16 Å2 ChemAxon Rotatable Bond Count 4 ChemAxon Refractivity 116.51 m3·mol-1 ChemAxon Polarizability 45.55 Å3 ChemAxon Number of Rings 6 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter Yes ChemAxon Veber's Rule No ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET features
Property Value Probability Human Intestinal Absorption + 0.9954 Blood Brain Barrier + 0.9708 Caco-2 permeable + 0.7322 P-glycoprotein substrate Substrate 0.9173 P-glycoprotein inhibitor I Inhibitor 0.7399 P-glycoprotein inhibitor II Non-inhibitor 0.7779 Renal organic cation transporter Non-inhibitor 0.6479 CYP450 2C9 substrate Non-substrate 0.8713 CYP450 2D6 substrate Substrate 0.7349 CYP450 3A4 substrate Substrate 0.7858 CYP450 1A2 substrate Non-inhibitor 0.9392 CYP450 2C9 inhibitor Non-inhibitor 0.8992 CYP450 2D6 inhibitor Non-inhibitor 0.6197 CYP450 2C19 inhibitor Non-inhibitor 0.8553 CYP450 3A4 inhibitor Non-inhibitor 0.8272 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.9294 Ames test Non AMES toxic 0.7862 Carcinogenicity Non-carcinogens 0.9372 Biodegradation Not ready biodegradable 0.9973 Rat acute toxicity 3.2955 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.8072 hERG inhibition (predictor II) Non-inhibitor 0.7219
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS Not Available Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Taxonomy
- Description
- This compound belongs to the class of organic compounds known as morphinans. These are polycyclic compounds with a four-ring skeleton with three condensed six-member rings forming a partially hydrogenated phenanthrene moiety, one of which is aromatic while the two others are alicyclic.
- Kingdom
- Organic compounds
- Super Class
- Alkaloids and derivatives
- Class
- Morphinans
- Sub Class
- Not Available
- Direct Parent
- Morphinans
- Alternative Parents
- Phenanthrenes and derivatives / Tetralins / Azaspirodecane derivatives / Coumarans / Aralkylamines / Alkyl aryl ethers / 1-hydroxy-2-unsubstituted benzenoids / Piperidines / Tertiary alcohols / Trialkylamines show 5 more
- Substituents
- Morphinan / Phenanthrene / Azaspirodecane / Tetralin / Coumaran / Alkyl aryl ether / 1-hydroxy-2-unsubstituted benzenoid / Aralkylamine / Piperidine / Benzenoid show 17 more
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- Not Available
Targets
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Agonist
- General Function
- Voltage-gated calcium channel activity
- Specific Function
- Receptor for endogenous opioids such as beta-endorphin and endomorphin. Receptor for natural and synthetic opioids including morphine, heroin, DAMGO, fentanyl, etorphine, buprenorphin and methadone...
- Gene Name
- OPRM1
- Uniprot ID
- P35372
- Uniprot Name
- Mu-type opioid receptor
- Molecular Weight
- 44778.855 Da
References
- Duttaroy A, Yoburn BC: In vivo regulation of mu-opioid receptor density and gene expression in CXBK and outbred Swiss Webster mice. Synapse. 2000 Aug;37(2):118-24. [PubMed:10881033]
- Melone M, Brecha NC, Sternini C, Evans C, Conti F: Etorphine increases the number of mu-opioid receptor-positive cells in the cerebral cortex. Neuroscience. 2000;100(3):439-43. [PubMed:11098106]
- Stafford K, Gomes AB, Shen J, Yoburn BC: mu-Opioid receptor downregulation contributes to opioid tolerance in vivo. Pharmacol Biochem Behav. 2001 May-Jun;69(1-2):233-7. [PubMed:11420091]
- Gomes BA, Shen J, Stafford K, Patel M, Yoburn BC: Mu-opioid receptor down-regulation and tolerance are not equally dependent upon G-protein signaling. Pharmacol Biochem Behav. 2002 May;72(1-2):273-8. [PubMed:11900797]
- Patel MB, Patel CN, Rajashekara V, Yoburn BC: Opioid agonists differentially regulate mu-opioid receptors and trafficking proteins in vivo. Mol Pharmacol. 2002 Dec;62(6):1464-70. [PubMed:12435815]
- Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Agonist
- General Function
- Opioid receptor activity
- Specific Function
- G-protein coupled receptor that functions as receptor for endogenous enkephalins and for a subset of other opioids. Ligand binding causes a conformation change that triggers signaling via guanine n...
- Gene Name
- OPRD1
- Uniprot ID
- P41143
- Uniprot Name
- Delta-type opioid receptor
- Molecular Weight
- 40368.235 Da
References
- Li JG, Benovic JL, Liu-Chen LY: Mechanisms of agonist-induced down-regulation of the human kappa-opioid receptor: internalization is required for down-regulation. Mol Pharmacol. 2000 Oct;58(4):795-801. [PubMed:10999950]
- Li JG, Zhang F, Jin XL, Liu-Chen LY: Differential regulation of the human kappa opioid receptor by agonists: etorphine and levorphanol reduced dynorphin A- and U50,488H-induced internalization and phosphorylation. J Pharmacol Exp Ther. 2003 May;305(2):531-40. Epub 2003 Jan 24. [PubMed:12606694]
- Marie N, Lecoq I, Jauzac P, Allouche S: Differential sorting of human delta-opioid receptors after internalization by peptide and alkaloid agonists. J Biol Chem. 2003 Jun 20;278(25):22795-804. Epub 2003 Apr 2. [PubMed:12672796]
- Sumner BE, Douglas AJ, Russell JA: Pregnancy alters the density of opioid binding sites in the supraoptic nucleus and posterior pituitary gland of rats. Neurosci Lett. 1992 Mar 30;137(2):216-20. [PubMed:1316589]
- Tao PL, Tsai CL, Chang LR, Loh HH: Chronic effect of [D-Pen2,D-Pen5]enkephalin on rat brain opioid receptors. Eur J Pharmacol. 1991 Aug 29;201(2-3):209-14. [PubMed:1665782]
- Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
- Niwa M, al-Essa LY, Ohta S, Kohno K, Nozaki M, Tsurumi K, Iwamura T, Kataoka T: Opioid receptor interaction and adenylyl cyclase inhibition of dihydroetorphine: direct comparison with etorphine. Life Sci. 1995;56(21):PL395-400. [PubMed:7739347]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Agonist
- General Function
- Opioid receptor activity
- Specific Function
- G-protein coupled opioid receptor that functions as receptor for endogenous alpha-neoendorphins and dynorphins, but has low affinity for beta-endorphins. Also functions as receptor for various synt...
- Gene Name
- OPRK1
- Uniprot ID
- P41145
- Uniprot Name
- Kappa-type opioid receptor
- Molecular Weight
- 42644.665 Da
References
- Niwa M, al-Essa LY, Ohta S, Kohno K, Nozaki M, Tsurumi K, Iwamura T, Kataoka T: Opioid receptor interaction and adenylyl cyclase inhibition of dihydroetorphine: direct comparison with etorphine. Life Sci. 1995;56(21):PL395-400. [PubMed:7739347]
- Wannemacher KM, Yadav PN, Howells RD: A select set of opioid ligands induce up-regulation by promoting the maturation and stability of the rat kappa-opioid receptor in human embryonic kidney 293 cells. J Pharmacol Exp Ther. 2007 Nov;323(2):614-25. Epub 2007 Aug 24. [PubMed:17720886]
- Gharagozlou P, Hashemi E, DeLorey TM, Clark JD, Lameh J: Pharmacological profiles of opioid ligands at kappa opioid receptors. BMC Pharmacol. 2006 Jan 25;6:3. [PubMed:16433932]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Agonist
- General Function
- Nociceptin receptor activity
- Specific Function
- G-protein coupled opioid receptor that functions as receptor for the endogenous neuropeptide nociceptin. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-b...
- Gene Name
- OPRL1
- Uniprot ID
- P41146
- Uniprot Name
- Nociceptin receptor
- Molecular Weight
- 40692.775 Da
References
- Hawkinson JE, Acosta-Burruel M, Espitia SA: Opioid activity profiles indicate similarities between the nociceptin/orphanin FQ and opioid receptors. Eur J Pharmacol. 2000 Feb 18;389(2-3):107-14. [PubMed:10688973]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Agonist
- General Function
- Zinc ion binding
- Specific Function
- E3 ubiquitin ligase involved in the retrotranslocation and turnover of membrane and secretory proteins from the ER through a set of processes named ER-associated degradation (ERAD). This process ac...
- Gene Name
- TRIM13
- Uniprot ID
- O60858
- Uniprot Name
- E3 ubiquitin-protein ligase TRIM13
- Molecular Weight
- 46987.08 Da
References
- Maneckjee R, Archer S, Zukin RS: Characterization of a polyclonal antibody to the mu opioid receptor. J Neuroimmunol. 1988 Feb;17(3):199-208. [PubMed:2828423]
- Stojilkovic SS, Dufau ML, Catt KJ: Opiate receptor subtypes in the rat hypothalamus and neurointermediate lobe. Endocrinology. 1987 Jul;121(1):384-94. [PubMed:3036471]
- Pesce G, Lang MA, Russell JT, Rodbard D, Gainer H: Characterization of kappa opioid receptors in neurosecretosomes from bovine posterior pituitary. J Neurochem. 1987 Aug;49(2):421-7. [PubMed:3037028]
- Pfeiffer A, Herz A: Discrimination of three opiate receptor binding sites with the use of a computerized curve-fitting technique. Mol Pharmacol. 1982 Mar;21(2):266-71. [PubMed:6124875]
- Audigier Y, Mazarguil H, Gout R, Cros J: Structure-activity relationships of enkephalin analogs at opiate and enkephalin receptors: correlation with analgesia. Eur J Pharmacol. 1980 Apr 11;63(1):35-46. [PubMed:6247160]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- General Function
- Type 4 melanocortin receptor binding
- Specific Function
- ACTH stimulates the adrenal glands to release cortisol.MSH (melanocyte-stimulating hormone) increases the pigmentation of skin by increasing melanin production in melanocytes.Beta-endorphin and Met...
- Gene Name
- POMC
- Uniprot ID
- P01189
- Uniprot Name
- Pro-opiomelanocortin
- Molecular Weight
- 29423.72 Da
References
- Sanchez-Blazquez P, Garzon J: Further characterization of alpha N-acetyl beta-endorphin-(1-31) regulatory activity, I: Effect on opioid- and alpha 2-mediated supraspinal antinociception in mice. Life Sci. 1992;50(26):2083-97. [PubMed:1318989]
- Xu JY, Fujimoto JM, Tseng LF: Involvement of supraspinal epsilon and mu opioid receptors in inhibition of the tail-flick response induced by etorphine in the mouse. J Pharmacol Exp Ther. 1992 Oct;263(1):246-52. [PubMed:1328609]
- Nicolas P, Li CH: Beta-endorphin-(1-27) is a naturally occurring antagonist to etorphine-induced analgesia. Proc Natl Acad Sci U S A. 1985 May;82(10):3178-81. [PubMed:2987913]
- Dum J, Gramsch C, Herz A: Activation of hypothalamic beta-endorphin pools by reward induced by highly palatable food. Pharmacol Biochem Behav. 1983 Mar;18(3):443-7. [PubMed:6132412]
- Lemaire S, Livett B, Tseng R, Mercier P, Lemaire I: Studies on the inhibitory action of opiate compounds in isolated bovine adrenal chromaffin cells: noninvolvement of stereospecific opiate binding sites. J Neurochem. 1981 Mar;36(3):886-92. [PubMed:6259293]
Drug created on July 31, 2007 07:09 / Updated on October 02, 2017 04:59